Literature DB >> 12732177

Runx3 is essential for the target-specific axon pathfinding of trkc-expressing dorsal root ganglion neurons.

Ken-ichi Inoue1, Shigeru Ozaki, Kosei Ito, Tsutomu Iseda, Saburo Kawaguchi, Masaharu Ogawa, Suk-Chul Bae, Namiko Yamashita, Shigeyoshi Itohara, Norio Kudo, Yoshiaki Ito.   

Abstract

Dorsal root ganglion (DRG) neurons project their axons to specific target layers in the gray matter of the spinal cord, according to their sensory modality (Neuron 30 (2001), 707; Cell 101 (2000), 485; Neuron 31 (2001), 59; J. Comp. Neurol. 380 (1997), 215; Sensory Neurons, Oxford Univ. Press, New York, 1992, p. 131). Expression of runt-related Runx/AML genes (Mech. Dev. 109 (2001), 413) on subtypes of DRG neurons suggests their involvement in lamina-specific afferent differentiation and maturation. Here we show that Runx3-/- mice display severe limb ataxia and abnormal posture and that most of them die shortly after birth. They show that proprioceptive afferent axons fail to reach the ventral horn and have a smaller dorsal funiculus in their spinal cords. Despite the strong resemblance of this phenotype to that of knockout mice deficient in neurotrophin-3 (NT-3) (Cell 77 (1994), 503; Nature 369 (1994), 658) and its receptor, trkC, (Nature 368 (1994), 249), which show proprioceptive afferent loss through selective neuronal cell death, Runx3-/- mice maintain normal number of TrkC/trkC positive DRG neurons throughout development. Our results suggest that Runx3 controls the target-specific axon pathfinding of trkC-expressing DRG neurons in the spinal cord.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12732177     DOI: 10.1016/s1079-9796(03)00032-9

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  8 in total

Review 1.  New functions for the proprioceptive system in skeletal biology.

Authors:  Ronen Blecher; Lia Heinemann-Yerushalmi; Eran Assaraf; Nitzan Konstantin; Jens R Chapman; Timothy C Cope; Guy S Bewick; Robert W Banks; Elazar Zelzer
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-09-24       Impact factor: 6.237

2.  Runx1 and Runx3 Are Downstream Effectors of Nanog in Promoting Osteogenic Differentiation of the Mouse Mesenchymal Cell Line C3H10T1/2.

Authors:  Tadahito Saito; Shinsuke Ohba; Fumiko Yano; Ichiro Seto; Yoshiyuki Yonehara; Tsuyoshi Takato; Toru Ogasawara
Journal:  Cell Reprogram       Date:  2015-06       Impact factor: 1.987

3.  An important role for RUNX3 in human L1 transcription and retrotransposition.

Authors:  Nuo Yang; Lin Zhang; Yue Zhang; Haig H Kazazian
Journal:  Nucleic Acids Res       Date:  2003-08-15       Impact factor: 16.971

4.  Subnuclear targeting of the Runx3 tumor suppressor and its epigenetic association with mitotic chromosomes.

Authors:  Sandhya Pande; Syed A Ali; Christopher Dowdy; Sayyed K Zaidi; Kosei Ito; Yoshiaki Ito; Martin A Montecino; Jane B Lian; Janet L Stein; Andre J van Wijnen; Gary S Stein
Journal:  J Cell Physiol       Date:  2009-03       Impact factor: 6.384

5.  Characterization of the Gbx1-/- mouse mutant: a requirement for Gbx1 in normal locomotion and sensorimotor circuit development.

Authors:  Desirè M Buckley; Jessica Burroughs-Garcia; Mark Lewandoski; Samuel T Waters
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

Review 6.  Role of RUNX in autoimmune diseases linking rheumatoid arthritis, psoriasis and lupus.

Authors:  Marta E Alarcón-Riquelme
Journal:  Arthritis Res Ther       Date:  2004-06-21       Impact factor: 5.156

7.  The Proprioceptive System Regulates Morphologic Restoration of Fractured Bones.

Authors:  Ronen Blecher; Sharon Krief; Tal Galili; Eran Assaraf; Tomer Stern; Yoram Anekstein; Gabriel Agar; Elazar Zelzer
Journal:  Cell Rep       Date:  2017-08-22       Impact factor: 9.423

8.  Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity.

Authors:  Myoung Sook Kim; Ramkishore Gernapudi; Eun Yong Choi; Rena G Lapidus; Antonino Passaniti
Journal:  Oncotarget       Date:  2017-08-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.